Pfizer starts Omicron-specific COVID-19 vaccine trial
The Hindu
The trial will involve 1,420 people aged 18-55.
Pfizer and its partner BioNTech have begun enrolment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies said in a statement on January 25.
Pfizer’s CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.

“I’ve never even been to these places before,” she laughed, “and suddenly I have memories in all of them.” The dates, she added, were genuinely good — long walks, easy conversations, and meals that stretched late into the evening — and the best part was that none of it felt heavy. The boys she met are all planning to visit her in Mumbai soon, not under without any pressure but with a sense of pleasant continuity. “I’m great,” she said, and she meant it.










